Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Kent

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Blood|August 26, 2025
Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemiaCristiana O'Brien, Nirvana Nursimulu, Anit Tyagi, et al.
Transplantation and Cellular Therapy|August 18, 2024
Outcomes of Haplo-Cord Versus Dual Cord Transplants: A Single-Center Retrospective AnalysisAndrew Kent, Kellen B Gil, Michael K Jones, et al.
Gastroenterology|May 24, 2015
Distinct and Synergistic Contributions of Epithelial Stress and Adaptive Immunity to Functions of Intraepithelial Killer Cells and Active Celiac DiseaseMala Setty, Valentina Discepolo, Valérie Abadie, et al.
American Journal of Hematology|February 13, 2026
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid LeukemiaMichael K Jones, Jesse Sanchez, Megan Connor, et al.
Eclinicalmedicine|October 27, 2025
Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trialDaniel A Pollyea, Brett M Stevens, Diana Abbott, et al.
Nature Immunology|October 27, 2014
A central role for Notch in effector CD8(+) T cell differentiationRonald A Backer, Christina Helbig, Rebecca Gentek, et al.
Haematologica|April 13, 2023
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemiaJonathan A Gutman, Amanda Winters, Andrew Kent, et al.
American Journal of Hematology|August 7, 2025
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid LeukemiaSomedeb Ball, Akriti G Jain, Najla Al Ali, et al.
Haematologica|February 26, 2026
Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapyJustin Watts, Ellen Madarang, Diana Abbott, et al.
The Veterinary Record|June 29, 2019
Call for coordinated antimicrobial approach at veterinary diagnostic laboratoriesFergus Allerton, John Fishwick, Susan Paterson, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Blood|August 26, 2025
Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemiaCristiana O'Brien, Nirvana Nursimulu, Anit Tyagi, et al.
Transplantation and Cellular Therapy|August 18, 2024
Outcomes of Haplo-Cord Versus Dual Cord Transplants: A Single-Center Retrospective AnalysisAndrew Kent, Kellen B Gil, Michael K Jones, et al.
Gastroenterology|May 24, 2015
Distinct and Synergistic Contributions of Epithelial Stress and Adaptive Immunity to Functions of Intraepithelial Killer Cells and Active Celiac DiseaseMala Setty, Valentina Discepolo, Valérie Abadie, et al.
American Journal of Hematology|February 13, 2026
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid LeukemiaMichael K Jones, Jesse Sanchez, Megan Connor, et al.
Eclinicalmedicine|October 27, 2025
Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trialDaniel A Pollyea, Brett M Stevens, Diana Abbott, et al.
Nature Immunology|October 27, 2014
A central role for Notch in effector CD8(+) T cell differentiationRonald A Backer, Christina Helbig, Rebecca Gentek, et al.
Haematologica|April 13, 2023
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemiaJonathan A Gutman, Amanda Winters, Andrew Kent, et al.
American Journal of Hematology|August 7, 2025
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid LeukemiaSomedeb Ball, Akriti G Jain, Najla Al Ali, et al.
Haematologica|February 26, 2026
Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapyJustin Watts, Ellen Madarang, Diana Abbott, et al.
The Veterinary Record|June 29, 2019
Call for coordinated antimicrobial approach at veterinary diagnostic laboratoriesFergus Allerton, John Fishwick, Susan Paterson, et al.
Pageof 7